JP2011525388A5 - - Google Patents

Download PDF

Info

Publication number
JP2011525388A5
JP2011525388A5 JP2011514898A JP2011514898A JP2011525388A5 JP 2011525388 A5 JP2011525388 A5 JP 2011525388A5 JP 2011514898 A JP2011514898 A JP 2011514898A JP 2011514898 A JP2011514898 A JP 2011514898A JP 2011525388 A5 JP2011525388 A5 JP 2011525388A5
Authority
JP
Japan
Prior art keywords
delivery system
eye
latanoprost
punctal plug
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011514898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525388A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/048452 external-priority patent/WO2010008883A1/en
Publication of JP2011525388A publication Critical patent/JP2011525388A/ja
Publication of JP2011525388A5 publication Critical patent/JP2011525388A5/ja
Pending legal-status Critical Current

Links

JP2011514898A 2008-06-24 2009-06-24 緑内障の併用治療 Pending JP2011525388A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7528408P 2008-06-24 2008-06-24
US61/075,284 2008-06-24
PCT/US2009/048452 WO2010008883A1 (en) 2008-06-24 2009-06-24 Combination treatment of glaucoma

Publications (2)

Publication Number Publication Date
JP2011525388A JP2011525388A (ja) 2011-09-22
JP2011525388A5 true JP2011525388A5 (https=) 2012-08-02

Family

ID=41431875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514898A Pending JP2011525388A (ja) 2008-06-24 2009-06-24 緑内障の併用治療

Country Status (7)

Country Link
US (1) US20090318549A1 (https=)
EP (1) EP2303184A4 (https=)
JP (1) JP2011525388A (https=)
CN (1) CN102105118A (https=)
CA (1) CA2728623A1 (https=)
TW (1) TW201012469A (https=)
WO (1) WO2010008883A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1765454T3 (en) 2004-07-02 2016-05-02 Mati Therapeutics Inc Device for submission of treatment medium to eye
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
NZ583858A (en) 2007-09-07 2012-08-31 Quadra Logic Tech Inc Lacrimal implant detection with detection device
CN102123713A (zh) * 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
US8591484B2 (en) 2010-09-15 2013-11-26 AlphaMed, Inc. Lacrimal punctum measurement and occlusion
US20120312840A1 (en) * 2011-05-13 2012-12-13 Ayako Hasegawa Container closure system with integral antimicrobial additives
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2755615B1 (en) 2011-09-14 2022-04-06 Forsight Vision5, Inc. Ocular insert apparatus
DK2911623T3 (da) 2012-10-26 2019-10-28 Forsight Vision5 Inc Oftalmisk system til langvarig frigivelse af lægemiddel til øjet
US20140206708A1 (en) * 2013-01-24 2014-07-24 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9424722B2 (en) * 2014-05-14 2016-08-23 Unlimited Liability, LLC Smart memory material lock devices
JP6555758B2 (ja) * 2014-09-22 2019-08-07 株式会社カネカ 内視鏡用注射器具
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US11291847B2 (en) * 2015-06-16 2022-04-05 The Regents Of The University Of Colorado, A Body Corporate Systems and methods for preventing, diagnosing, and/or treating one or more medical conditions via neuromodulation
CN105879126A (zh) * 2016-03-24 2016-08-24 杭州亚慧生物科技有限公司 一种超润滑血清白蛋白泪点塞及其制备方法
EP3773330B1 (en) * 2018-03-29 2025-03-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
CN109568138B (zh) * 2019-01-10 2021-06-25 新疆国际旅行卫生保健中心 药片分割装置
US12447045B2 (en) 2019-10-02 2025-10-21 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US11207267B2 (en) 2019-10-02 2021-12-28 Segal Innovations LLC Bio-adhesive dissolving compounds and device
US12023276B2 (en) 2021-02-24 2024-07-02 Ocular Therapeutix, Inc. Intracanalicular depot inserter device

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US5589563A (en) * 1992-04-24 1996-12-31 The Polymer Technology Group Surface-modifying endgroups for biomedical polymers
CA2134087C (en) * 1992-04-24 2007-07-17 Robert S. Ward Copolymers and non-porous, semi-permeable membrane thereof and its use for permeating molecules of predetermined molecular weight range
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
ES2172415B2 (es) * 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
CA2513751C (en) * 2003-01-24 2012-01-10 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
EP1603485A4 (en) * 2003-02-26 2011-03-30 Medivas Llc BIOACTIVE STENTS AND METHOD OF USE THEREOF
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) * 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
US20050232972A1 (en) * 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2007047744A2 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Method for treating primary and secondary forms of glaucoma
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
MX2009006146A (es) * 2006-12-18 2009-06-19 Alcon Res Ltd Dispositivos y metodos para la administracion de farmacos oftalmicos.
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
CN102670352A (zh) * 2007-09-07 2012-09-19 Qlt股份有限公司 用于泪腺植入物的插入和抽出工具
CA2698508C (en) * 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
SG188155A1 (en) * 2008-02-18 2013-03-28 Quadra Logic Tech Inc Lacrimal implants and related methods
WO2009134371A2 (en) * 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
CN102123713A (zh) * 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送

Similar Documents

Publication Publication Date Title
JP2011525388A5 (https=)
NZ588938A (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
Chang Use of Malyugin pupil expansion device for intraoperative floppy-iris syndrome: results in 30 consecutive cases
JP2011520805A5 (https=)
Miller et al. Medical anti‐glaucoma therapy: Beyond the drop
JP2019532931A (ja) 眼瞼炎の治療に使用するための医薬組成物
JP2016028091A5 (https=)
MX2011007804A (es) Suministro de liberación sostenida de uno o más agentes.
JP2008538215A5 (https=)
SG170816A1 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
JP2018513117A5 (https=)
JP2021059554A (ja) 増殖性硝子体網膜症用メトトレキサート
WO2012092510A3 (en) Ocular drug delivery system
JP2016121163A (ja) 眼内でのコルチコステロイド使用に伴う眼圧の発生を減少させる方法
Pavan-Langston et al. Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy
Tan et al. Ab-externo implantation of XEN gel stent for refractory steroid-induced glaucoma after lamellar keratoplasty
Pereira et al. Choroidal detachment after the use of topical latanoprost
Li et al. Chinese expert consensus on perioperative medication in laser corneal refractive surgeries (2019)
Uña et al. Perioperative pharmacological management in patients with glaucoma
JP2015520628A5 (https=)
WO2011163356A2 (en) Methods of treating conditions associated with overactive bladder
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
Gagliardi et al. Two cases of therapeutic scleral lenses for KID syndrome
RU2335263C1 (ru) Способ лечения начальной стадии возрастной катаракты
Etter et al. Eyelash migration into a clear corneal incision following cataract surgery